Metastatic melanoma in lungs describes stage IV disease where melanoma cells spread from the skin or original site to one or both lungs. This advanced form changes treatment goals, outlook, and monitoring strategies compared with earlier stages.
Understanding how melanoma behaves in the lungs helps patients and teams coordinate targeted therapy, immunotherapy, and supportive care. The following sections focus on specific aspects of metastatic melanoma affecting the lungs.
| Clinical Feature | Presentation | Common Management Approach |
|---|---|---|
| Metastatic burden | Lung nodules or masses, possible pleural involvement | Imaging surveillance, biopsy for molecular profiling |
| Symptoms | Shortness of breath, cough, chest pain, reduced exercise tolerance | Symptom-directed care, oxygen, palliative procedures |
| Systemic therapy options | Immunotherapy, targeted therapy, chemotherapy, clinical trials | Multidisciplinary decision based on biomarkers and fitness |
| Prognostic factors | Mutation status, number of lung lesions, performance status, prior treatments | Guides choice and sequencing of systemic and local therapies |
Molecular Testing and Treatment Matching for Metastatic Melanoma in Lungs
Comprehensive genomic profiling is essential before starting systemic therapy for metastatic melanoma with lung involvement.
Key Biomarkers Guiding Therapy
- BRAF V600E or V600K mutations respond well to BRAF inhibitors.
- NRAS mutations may qualify patients for MEK inhibitors or immunotherapy.
- KIT mutations are rare in melanoma but alter therapeutic options in specific contexts.
- PD-L1 and tumor mutational burden help predict response to checkpoint inhibitors.
Systemic Therapy Approaches for Metastatic Melanoma in Lungs
Treatment plans for melanoma metastatic to the lungs are tailored to mutation status, symptom burden, and prior therapies.
Immunotherapy Options
- PD-1 inhibitors such as pembrolizumab or nivolumab are common first-line choices.
- Combination regimens, including CTLA-4 plus PD-1, may be used in selected patients.
Targeted Therapy for Mutant Disease
- BRAF inhibitors (vemurafenib, dabrafenib) often produce rapid responses.
- MEK inhibitors (trametinib, cobimetinib) are paired with BRAF inhibitors to delay resistance.
Local and Supportive Measures for Lung Metastases
While systemic therapy addresses widespread disease, local strategies can manage lung-specific complications.
Procedures and Symptom Control
- Stereotactic body radiotherapy can treat limited lung lesions with precision.
- Pleural procedures may relieve malignant effusions causing breathlessness.
- Oxygen therapy and pulmonary rehabilitation improve daily function.
Monitoring Response and Progression in the Lungs
Regular imaging, typically with CT, helps assess how metastatic melanoma in the lungs responds to therapy.
Patterns of Response and Progression
- Partial or complete radiographic response indicates treatment efficacy.
- New or growing lesions trigger re-biopsy and consideration of alternative therapies.
- Serial scans and symptom tracking guide timing of switches in systemic treatment.
Key Takeaways for Patients and Care Teams
- Confirm actionable mutations through comprehensive genomic profiling.
- Align systemic therapy with PD-L1, tumor mutational burden, and prior treatment history.
- Integrate local approaches such as radiotherapy for symptom control in the lungs.
- Use structured imaging intervals to monitor response and guide timely therapy switches.
- Coordinate medical, supportive, and palliative strategies to optimize quality of life.
FAQ
Reader questions
What are common symptoms when melanoma spreads to the lungs?
Shortness of breath, persistent cough, chest discomfort, and reduced ability to exercise are typical symptoms when melanoma involves the lungs. Some patients may also experience fatigue or weight loss if the disease is advanced.
How is metastatic melanoma in lungs diagnosed and staged?
Diagnosis involves imaging such as CT or PET-CT, followed by biopsy of lung lesions for pathology and molecular testing. Staging considers the number and size of lung metastases, involvement of other organs, and the patient’s overall health.
What systemic treatments are typically used for lung metastases from melanoma?
Systemic options include immunotherapy with PD-1 or combination regimens, targeted therapy for BRAF-mutant disease, and chemotherapy in select cases. The choice depends on biomarker status, prior treatments, and patient fitness.
Can localized lung lesions be treated separately in metastatic melanoma?
Yes, procedures like stereotactic radiotherapy, surgery, or ablation may be used for limited lung metastases to control symptoms or local progression while continuing systemic therapy for widespread disease.